Alarcon GS, et al. Systemic lupus erythematosus in three ethnic groups. Arthritis and Rheumatism 1998;41(7):1173-1180.

Black J, Jacobs E. Luckmann's and Sorensen's Medical-Surgical Nursing: A Psychological Approach, 6th edition. Philadelphia (PA): W.B. Saunders, 2000.

Boumpas T, et al. Systemic lupus erythematosus: Emerging concepts. Part I: Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Annals of Internal Medicine 1995;122(12):940-950.

Boumpas T, et al. Systemic lupus erythematosus: Emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Annals of Internal Medicine 1995;123(1):42-53.

Brucato A, et al. Fourth international workshop on neonatal lupus syndromes and the Ro/SSA-La/SSB system. Clinical and Experimental Rheumatology 1999;17(1):130-136.

Buyon JP, et al. Autoimmune-associated congenital heart block: Demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. Journal of the American College of Cardiology 1998;31(7):1658 1666.

Buyon JP. Hormone replacement therapy in postmenopausal women with systemic lupus erythematosus. Journal of the American Women's Medical Association 1998;53(1):13-17.

Buyon JP. The effects of pregnancy on autoimmune disease. Journal of Leukocyte Biology 1998;63(3):281-287.

Dibner R, Colman C. Lupus Handbook for Women. New York (NY): Simon & Schuster, 1994.

Friedman A, et al. Systemic lupus erythematosus in three ethnic groups. Part IV: Factors associated with selfreported functional outcome in a large cohort study. Arthritis and Rheumatism 1999;12(4):256-266.

Gladman DD, et al. The systemic lupus international collaborating clinics/ American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. The Journal of Rheumatology 2000;27(2):373-376.

Horstman J. The Arthritis Foundation's Guide to Alternative Therapies. Atlanta (GA): Arthritis Foundation, 1999.

Kassan SS. Sjogren's Syndrome and Systemic Lupus Erythematosus. Rockville (MD): Lupus Foundation of America, Inc., 1999; pamphlet.

Katz RS. Steroids in the Treatment of Lupus. Rockville (MD): Lupus Foundation of America, Inc., 1999; pamphlet.

Klippel JH. Immunosuppressive therapy: Antimalarials, cytotoxic agents, and azathioprine. In: Klippel JH, Dieppe PA, editors. Rheumatology. St. Louis (MO): Mosby Year-Book, 1994, pp. 933-943.

Klippel JH. Kidney Disease and Lupus. Rockville (MD): Lupus Foundation of America, Inc., 1999; pamphlet.

Klippel JH. Medications and Systemic Lupus Erythematosus. Rockville (MD): Lupus Foundation of America, Inc., 1999; pamphlet.

Klippel JH, editor. Primer on the Rheumatic Diseases, 11th edition. Atlanta (GA): Arthritis Foundation, 1997.

Lahita RG. What Is Lupus? Rockville (MD): Lupus Foundation of America, Inc., 1998; pamphlet.

Lahita RG. .Que Es Lupus? Rockville (MD): Lupus Foundation of America, Inc., 2000; pamphlet in Spanish.

Libby D, White DA. Thoracic manifestations of the systemic autoimmune diseases. Clinics in Chest Medicine 1998;19(4):809-821.

Looney RJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus. Arthritis and Rheumatism. 2004;50(8):2580-2589.

McClain MT, et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nature Medicine 2005;11(1):85-89.

Medical Economics Company. The PDR Family Guide to Prescription Drugs, 9th edition. New York (NY): Crown Books, 2002.

Moore AD, et al. The use of alternative medical therapies in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2000;43(6):1410-1418.

Murin S, et al. Pulmonary manifestations of systemic lupus erythematosus. Clinics in Chest Medicine 1998;19(4):641-665.

National Institute of Arthritis and Musculoskeletal and Skin Diseases. Accelerated atherosclerosis in systemic lupus erythematosus. Summary of September 8-9, 1999, workshop. (http:// www.niams.nih.gov/ne/reports/sci_ wrk/1999/aasleagenda.htm)

National Institute of Arthritis and Musculoskeletal and Skin Diseases. Genetic risk factor identified for lupus kidney disease in African Americans. News release. Bethesda (MD): NIAMS, March 6, 1996. (http://www.niams.nih. gov/ne/press/1996/03_06.htm)

National Institute of Arthritis and Musculoskeletal and Skin Diseases. Neuropsychiatric manifestations of systemic lupus erythematosus. Summary of May 24-25, 1999 workshop. (http:// www.niams.nih.gov/ne/reports/sci_ wrk/1999/agendanmsle.htm)

National Institute of Arthritis and Musculoskeletal and Skin Diseases. NIAMS establishes lupus registry and repository. News release. Bethesda (MD): NIAMS, January 15, 1996. (http://www. nih.gov/niams/news/lupusini.htm#tosnr)

Nguyen QD, Foster CS. Systemic lupus erythematosus and the eye. International Ophthalmology Clinics 1998;38(1):33-60

Nidus Information Services. Systemic Lupus Erythematosus. Well-Connected [serial online] 2000. Retrieved from MD Consult on the World Wide Web. (http://home.mdconsult.com/das/patient/ body/37439093/41/5494.htr)

Pelle MT, Werth VP. Thalidomide in cutaneous lupus erythematosus. American Journal of Clinical Dermatology 2003;4(6)379-387

Petri M. Pregnancy in SLE. Bailliere's Clinical Rheumatology 1998;12(3): 449-476.

Petri M, et al. Results of the GL701 (DHEA) multicenter steroid-sparing SLE study. Arthritis and Rheumatology 1997;40(suppl):S327.

Provost TT. Skin Disease in Lupus. Rockville (MD): Lupus Foundation of America, Inc., 1998; pamphlet.

Ramsey-Goldman R, et al. Frequency of fractures in women with systemic lupus erythematosus. Arthritis and Rheumatism 1999;42(5):882-890.

Reveille JD, et al. Systemic lupus erythematosus in three ethnic groups. Part I: The effects of HLA class II, C4 and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis and Rheumatism 1998;41(7):1161 1172.

Rubin RL. Drug-Induced Lupus Erythematosus. Rockville (MD): Lupus Foundation of America, Inc., 1999; pamphlet.

Sabir SM, Werth VP. Cutaneous manifestations of lupus erythematosus. The Journal of Musculoskeletal Medicine 1999;16(8):482-491.

Schur PH, editor. The Clinical Management of Systemic Lupus Erythematosus, 2nd edition. Philadelphia (PA): Lippincott Williams & Wilkins, 1996.

Schwartz RS. Blood Disorders in SLE. Rockville (MD): Lupus Foundation of America, Inc., 1996.

Seligman VA, et al. The Fcã receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non- Caucasians. Arthritis and Rheumatism 2001;44(3):618-625.

Shapiro HS. Depression in Lupus. Rockville (MD): Lupus Foundation of America, Inc., 1998; pamphlet.

Slater CA, et al. Preserving ovarian function in patients receiving cyclo phosphamide. Lupus 1999;8(1):3-10.

Thumboo J, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. The Journal of Rheumatology 2000;26(6):1414-1420.

Traynor AE, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase 1 study. The Lancet 2000;356(9231):701-707.

Thomson Micromedex. USP DI@ Volume I: Drug Information for the Health Care Professional, Volume 1, 24th edition. Rockville (MD), 2004.

Van Vollenhoven RF, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. Journal of Rheumatology 1998;25:285-289.

Wallace DJ, Metzger AL. Lupus and Infections and Immunizations. Rockville (MD): Lupus Foundation of America, Inc., 1995.

Wiseman MH, et al. Treatment of Rheumatic Diseases: A Companion to Kelly's Textbook of Rheumatology, 2nd edition. Philadelphia (PA): W.B. Saunders, 2000.

Zonana-Nacach A, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis and Rheumatism 2000;43(8):1801-1808.



Source: National Institutes of Health, U.S.Dept of Health and Human Services